Finch Therapeutics Q2 2022 net loss $22.7M; revenue down $2.5M YoY

Finch Therapeutics Group, Inc.

2023-Q2 EPS reported -$29.82 revenue$715,000

Net loss of $22.7M vs $15.2M in Q2 2021; R&D flat at $13.9M; G&A up to $8.2M.
Revenue fell primarily due to Takeda agreement amendment; prior period had $1.8M PPP loan gain.
Cash $104.7M as of June 30, 2022 (down from $133.5M Dec 2021); funds operations into Q1 2024.
On track to start enrollment in PRISM4 Phase 3 CP101 trial in H2 2022; topline data expected H1 2024.
PRISM-EXT results accepted for ACG 2022; FIN-211 IND submission on track for Q4 2022.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.